Pricing power led
The tape rewarded two things: the ability to raise price and tangible progress in the “real economy” backlog. With costs and tariffs creeping higher, margin defense is the trade, and the market paid for it.
GrafTech (GRAF) surged after raising prices for graphite electrodes. Steel inputs are back in focus, supply constraints are back in the narrative, and positioning looked light enough that it didn’t take much to spark a fast move.
In semis, Intel (INTC) traded higher on reports it’s poised to raise PC chip prices again due to rising supply-chain costs. This wasn’t a “PC demand is ripping” day. It was a reminder that if you can push price without cratering volumes, the margin conversation gets less ugly.
Critical minerals kept a bid as well. American Battery Technology (ABAT) moved up after its Nevada lithium project was accepted by the U.S. Bureau of Land Management. It’s not a flashy catalyst, but it tightens timelines and pulls capital toward names clearing gates instead of selling hope.
Tariffs hit the tape
Trade policy wasn’t background noise. Canada’s retaliatory tariffs of CA$27.6 billion on U.S. goods took effect, including doubling steel and aluminum duties to 50%. The sorting was simple: domestic-ish price setters up, cross-border exposure down.
Bombardier (BDRBF) fell as the U.S.-Canada trade dispute intensified and import duties rose. Tariffs don’t need to show up in next quarter’s delivery numbers to pressure a stock. They muddy input costs, schedules, and end-demand sensitivity—and when the underwriting turns into customs math, multiples tend to compress.
That’s why the tape preferred “I can push price” (GRAF, INTC) and “I cleared a gating item” (ABAT) over businesses likely forced to wear the friction.
Clean headlines, strict grading
Event-driven money showed up, but it wasn’t generous. Clean terms got a nod. Anything that reopened the debate got hit.
John Marshall Bank (JMBS/JM) was flat after agreeing to acquire Eagle Financial Services (EFSI) in an approximately $253 million all-stock deal. That’s typical for bank M&A: once the headline prints, it becomes a spreadsheet exercise—deposit mix, credit, cost saves, and exchange math in a sector still trading off rate expectations.
In defense, L3Harris (LHX) was flat to slightly higher after being selected by the U.S. Navy to supply counter-drone systems. For a large prime, contract wins are usually incremental rather than a new valuation regime. Still, counter-drone is a live procurement lane, so the headline supports the stock even if it doesn’t ignite it.
Healthcare was less forgiving. Biohaven (BHVN) dropped after an RBC downgrade following its agreement involving SK Biopharma. In biotech, a deal headline doesn’t buy immunity if the sell-side reframes the economics or the risk. When the Street decides the upside was already there, the stock doesn’t get to negotiate.
What mattered
- Price increases worked. GRAF and INTC were rewarded for trying to pass through costs.
- Tariffs were a real factor. Cross-border exposure like BDRBF got marked down on uncertainty.
- Milestones beat narratives. ABAT benefited from a concrete regulatory step.
- Catalysts were graded harshly. JMBS/JM and LHX held steady; BHVN didn’t.
The market bought throughput and pricing power, and sold anything that looked like it needed a trade lawyer to hit its numbers.